Is Frequent Imaging Necessary? Impact of Computed Tomography During Follow-up After Surgical Treatment for Nonmetastatic Renal Cell Carcinoma: A Systematic Review

被引:0
作者
van den Brink, Luna [1 ,2 ]
Reijerink, Marlin A. A. [3 ]
Henderickx, Michael M. E. L. [1 ]
Bex, Axel [4 ,5 ]
Jamaludin, Faridi S. [6 ]
Beerlage, Harrie P. [1 ,2 ]
van Delden, Otto M. [3 ]
van Moorselaar, Reindert J. A. [7 ]
Stoker, Jaap [2 ,3 ]
Bipat, Shandra [3 ]
Zondervan, Patricia J. [1 ,2 ]
机构
[1] Univ Amsterdam, Dept Urol, Amsterdam UMC, Amsterdam, Netherlands
[2] Canc Ctr Amsterdam, Imaging & Biomarkers, Amsterdam, Netherlands
[3] Univ Amsterdam, Dept Radiol & Nucl Med, Amsterdam UMC, Amsterdam, Netherlands
[4] Netherlands Canc Inst NKI, Dept Urol, Amsterdam, Netherlands
[5] Royal Free Hosp, Dept Urol, London, England
[6] Univ Amsterdam, Med Lib AMC, Amsterdam UMC, Amsterdam, Netherlands
[7] Vrije Univ, Dept Urol, Amsterdam UMC, Amsterdam, Netherlands
关键词
Follow-up; Imaging; Recurrences; Renal cell carcinoma; PARTIAL NEPHRECTOMY; RADICAL NEPHRECTOMY; ADJUVANT SUNITINIB; HIGH-RISK; FUNCTIONAL OUTCOMES; DOUBLE-BLIND; SURVEILLANCE; SURVIVAL; CANCER; RECURRENCE;
D O I
10.1016/j.euo.2024.11.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and objective: Current guidelines on radiological follow-up (FU) for patients after treatment for nonmetastatic renal cell carcinoma (RCC) are not based on robust evidence. This review aims to evaluate whether the 2022 European Association of Urology (EAU) guidelines are noninferior, in terms of recurrence and (overall) survival, to a higher imaging frequency of computed tomography (CT) of the chest and abdomen. Methods: A literature search of relevant search machines (PubMed/Medline and EMBASE) was performed up to May 29, 2024. Studies describing patients with non-metastatic RCC who underwent curative treatment by means of partial or radical nephrectomy were included. Studies with a higher number of CT scans than recommended by the EAU were compared with those that followed guidelines by examining recurrences and survival data. Outcomes were classified into risk groups according to the 2022 EAU guidelines. Key findings and limitations: Twenty studies met our inclusion criteria. Sixteen (80%) studies employed a higher imaging frequency during FU compared with 2022 EAU guideline recommendations, two studies (10%) followed the guidelines, and two studies (10%) performed less imaging. Recurrences were rare in low-risk studies (0-7.6%) and varied among high-risk studies, ranging between 33% and 40% in randomized controlled trials and 11% and 28% in retrospective studies. A meta-analysis was not suited due to clinical diversity, and the risk of bias was high among cohort studies. Conclusions and clinical implications: Most studies employ a higher imaging frequency during FU after treatment for nonmetastatic RCC than recommended by the 2022 EAU guidelines. Survival and recurrence rates suggest that more frequent imaging than recommended by the EAU may not be advantageous, although high-quality evidence is needed to further improve guidelines. Patient summary: In this review, we assessed radiological follow-up schedules for patients after surgery for kidney cancer and compared these with the follow-up sched-ules recommended by the European Association of Urology guidelines. We found that most studies apply more frequent imaging during follow-up than recommended by guidelines, although survival and recurrence rates are similar among studies with differ-ent imaging frequencies. We conclude that more frequent imaging than recommended by guidelines may not be necessary and that prospective studies are needed to deter-mine whether imaging can be reduced further during follow-up. (c) 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).
引用
收藏
页码:829 / 840
页数:12
相关论文
共 54 条
[21]   Cost of upper tract imaging obtained during hematuria evaluation: Analysis of a national claims database [J].
Hannemann, Alex ;
Pessoa, Rodrigo Rodrigues ;
Flaig, Thomas ;
Kuna, Elizabeth Molina ;
Warren, Adam ;
Robin, Tyler ;
Kim, Simon P. ;
Ballon-Landa, Eric .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (08) :246e1-246e5
[22]   Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease [J].
Janzen, NK ;
Kim, HL ;
Figlin, RA ;
Belldegrun, AS .
UROLOGIC CLINICS OF NORTH AMERICA, 2003, 30 (04) :843-+
[23]  
Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]
[24]   Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials [J].
Leibovich, BC ;
Blute, ML ;
Cheville, JC ;
Lohse, CM ;
Frank, I ;
Kwon, ED ;
Weaver, AL ;
Parker, AS ;
Zincke, H .
CANCER, 2003, 97 (07) :1663-1671
[25]   European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update [J].
Ljungberg, Borje ;
Albiges, Laurence ;
Abu-Ghanem, Yasmin ;
Bedke, Jens ;
Capitanio, Umberto ;
Dabestani, Saeed ;
Fernandez-Pello, Sergio ;
Giles, Rachel H. ;
Hofmann, Fabian ;
Hora, Milan ;
Klatte, Tobias ;
Kuusk, Teele ;
Lam, Thomas B. ;
Marconi, Lorenzo ;
Powles, Thomas ;
Tahbaz, Rana ;
Volpe, Alessandro ;
Bex, Axel .
EUROPEAN UROLOGY, 2022, 82 (04) :399-410
[26]   Comparison of Renal Cell Carcinoma Surveillance Guidelines: Competing Trade-Offs [J].
Lobo, Jennifer M. ;
Nelson, Marc ;
Nandanan, Naveen ;
Krupski, Tracey L. .
JOURNAL OF UROLOGY, 2016, 195 (06) :1664-1670
[27]   A protocol for the development of core outcome sets for effectiveness trials and clinical audits in renal cell cancer (R-COS) [J].
Maclennan, Steven ;
Wintner, Lisa M. ;
Beyer, Katharina ;
Lawlor, Ailbhe ;
Tripathee, Sheela ;
Dabestani, Saeed ;
Marconi, Lorenzo ;
Giles, Rachel H. ;
Woodward, Rose ;
Van Hemelrijck, Mieke ;
Bex, Axel ;
Zondervan, Patricia .
BJUI COMPASS, 2023, 4 (05) :504-512
[28]   Epidemiology and Prevention of Renal Cell Carcinoma [J].
Makino, Tomoyuki ;
Kadomoto, Suguru ;
Izumi, Kouji ;
Mizokami, Atsushi .
CANCERS, 2022, 14 (16)
[29]   Effective doses in radiology and diagnostic nuclear medicine: A catalog [J].
Mettler, Fred A., Jr. ;
Huda, Walter ;
Yoshizumi, Terry T. ;
Mahesh, Mahadevappa .
RADIOLOGY, 2008, 248 (01) :254-263
[30]   Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial [J].
Motzer, Robert J. ;
Russo, Paul ;
Gruenwald, Viktor ;
Tomita, Yoshihiko ;
Zurawski, Bogdan ;
Parikh, Omi ;
Buti, Sebastiano ;
Barthelemy, Philippe ;
Goh, Jeffrey C. ;
Ye, Dingwei ;
Lingua, Alejo ;
Lattouf, Jean-Baptiste ;
Albiges, Laurence ;
George, Saby ;
Shuch, Brian ;
Sosman, Jeffrey ;
Staehler, Michael ;
Vazquez Estevez, Sergio ;
Simsek, Burcin ;
Spiridigliozzi, Julia ;
Chudnovsky, Aleksander ;
Bex, Axel .
LANCET, 2023, 401 (10379) :821-832